After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Wall Street enters the thick of earnings reporting in week three of the season with heavyweights Apple and Alphabet on tap.
AMGN is neutral now, but a close below $158 weakens the chart picture.
Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.
Brad Loncar, CEO of Loncar Investment said don't throw in the towel on biotech stocks yet.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.